Zydus Therapeutics announces positive topline results from EPICS-III Phase 2b/3 trial of Saroglitazar in Primary Biliary Cholangitis

PharmaShots Weekly Snapshots (Nov 10, 2025 – Nov 14, 2025)     

DRRA20 minutes ago 0

Adagene Enters ~$845M Licensing Deal with Third Arc Bio to Develop Masked CD3 T Cell Engagers

DRRA1 hour ago 0

Kura scores FDA okay for rival to Syndax’s leukaemia drug

DRRA2 hours ago 0

Kura and Kyowa Kirin secure FDA go-ahead for targeted leukaemia therapy

DRRA3 hours ago 0